Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients

Bengü Tatar; Ayse Acar; Pelın Adar; Sukran Kose

doi:10.5114/ceh.2020.93058

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 6

Send email

Copy url:

abstract:

Original paper

Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients

Bengü Tatar

¹

,

Ayse Acar

¹

,

Pelın Adar

¹

,

Sukran Kose

¹

Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Izmir Tepecik Education and Research Hospital, Turkey

Clin Exp HEPATOL 2020; 6, 1: 55–59

DOI: https://doi.org/10.5114/ceh.2020.93058

Online publish date: 2020/02/17

View full text Get citation

PlumX metrics:

Aim of the study
The quantitative hepatitis B surface antigen (qHBsAg) level indicates the amount of transcriptional activity of covalently closed circular DNA (cccDNA) and integrated DNA in hepatocytes which plays a role in development of chronic hepatitis B (CHB) and may help decide whether the treatment is necessary or not. The aim of this study is to evaluate the association between serum qHBsAg levels and viral replication and stage of liver fibrosis in treatment-naive CHB patients and to determine the role of qHBsAg levels in predicting when liver biopsy is necessary.

Material and methods
967 patients were included in the study. Because of refusal of liver biopsy the study was conducted on 123 patients. The association between qHBsAg levels with HBV DNA, a-fetoprotein, fibrosis stage and histology activity index was evaluated.

Results
Of the patients, mean age was 48 ±11.2 years and 56.1% were male. We found that patients with HBV DNA ≥ 2000 IU/ml had a higher qHBsAg titer in comparison with HBV DNA < 2000 IU/ml. However, there was no relationship between qHBsAg titer and liver necroinflammation or fibrosis stage.

Conclusions
Monitoring of qHBsAg together with HBV DNA may be helpful in CHB management. However, qHBsAg level does not provide knowledge about the timing of biopsy or the decision of CHB treatment.

keywords:

Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients

Bengü Tatar 1 , Ayse Acar 1 , Pelın Adar 1 , Sukran Kose 1

chronic hepatitis B, quantitative hepatitis B surface antigen, liver biopsy, hepatocytes

Bengü Tatar

¹

,

Ayse Acar

¹

,

Pelın Adar

¹

,

Sukran Kose

¹